



**INGEN TECHNOLOGIES SECURES STRATEGIC CONTRACT WITH  
TOTAL HEALTHCARE COMPLIANCE, INC.  
-ANTICIPATES ADDITIONAL ANNUAL REVENUES OF \$2M-**

*For Immediate Release:*

**Calimesa, CA- January 18, 2005:** Ingen Technologies, Inc. (OTC:IGTN) announced today that 2004 unaudited revenues have increased 14% over 2003, with substantial growth expected in the first quarter of 2005.

Additionally, Ingen recently signed a contract with Total Healthcare Compliance, Inc., a medical service provider to third party medical networks and direct physician services throughout the country, that is expected to boost revenues associated with the Company's Secure Balance™ program of an additional \$200,000 per month, or \$2M per year.

"Reports indicate that the Company's Secure Balance™ products have applications to 350,000 physician and hospital based programs with a total demand of 250,000 units." Said Scott Sand, CEO & Chairman. "Secure Balance™ expects to sell to 5% of the market with initial market penetration of less than 1% over the next 2 years."

Sand continued, "This would represent approximately 1,000 units and revenues of over \$50M during the next 24 months. These numbers are achievable now that the company has contracted with several industry leaders to create a distribution channel for Secure Balance™."

The Company also announced that it has engaged Spector & Wong, LLP to complete the necessary audits for SEC filings. This audit is expected to be complete in February, 2005.

"Spector & Wong has been our CPA firm for the past 6 years and has kept the company's tax filings, books and records current. This firm has 20 years experience with SEC audits and filings. It was necessary to reorganize CRTZ prior to any audits." Said Scott Sand, CEO & Chairman of Ingen Technologies.

## **About Ingen Technologies**

Ingen Technologies, Inc. is a public company trading on OTC: IGTN. In business since 1999, Ingen Technologies went public in March-2004, and is a growth-oriented technology company that offers a diverse and progressive service and product line.

The Company's flagship products are its BAFI™, GasAlert™ and OxyAlert™ products, the world's first wireless digital low gas warning system for pressurized gas cylinders. The BAFI™ received a US Patent on October 24<sup>th</sup>, 2000, Patent No. 6,137,417. BAFI™, now in its second generation, is an accurate and cost-effective, real-time pressurized gas warning system that will alert users when gas levels are approaching empty.

The OxyAlert™ and GasAlert™ product lines have multiple applications, inclusive of, but not limited to, the Medical Industry, Home Consumer, Residential Development Industry, Safety & Protection (fire and police), Aircraft Industry, and the Recreational Vehicle Industry. BAFI™ is a patented product that meets or exceeds regulatory compliance of this type of product and is completed and in production.

The successful Secure Balance™ program is equipment, training and an educational support system available to physicians throughout the United States. During the initial twelve months, the Secure Balance™ system generated approximately \$1 million in revenues for Ingen and is now being aggressively marketed throughout the United States. More recently, the company's sales have increased in proportion to the expansion of the Company's marketing network. Its marketing strength is based upon superior products and an experienced professional team.

The Secure Balance™ program offers the most sophisticated clinical products for vestibular function testing and balance therapy compared to any of their competitors. "We offer the most medically accepted, comprehensive product line for vestibular function testing and balance therapy, at prices lower than our competition," said Scott Sand, CEO of Ingen Technologies. With more than two million people visiting their doctor each year complaining of dizziness and vertigo; the Secure Balance™ program can substantially help patients regain their balance and decrease the number of fall related injuries. The elderly population is expected to double over the next decade and comprise the majority of balance disorder patients. This is an expanding market.

For more information, visit: [www.otcfn.com/igttn](http://www.otcfn.com/igttn) and [www.ingen-tech.com](http://www.ingen-tech.com)

Investor Relations Contact: Scott R. Sand, C.E.O & Chairman  
Ingen Technologies, Inc.  
285 E. County Line Road  
Calimesa, CA 92320  
800-259-9622  
951-675-3266  
800-777-1186 FAX  
scottsand@ingen-tech.com

Rick McCaffrey, Investor Relations  
OTC Financial Network  
781-444-6100 x625  
781-444-6101 FAX  
rick@otcfn.com

**Safe Harbor for Forward-Looking Statements:** *This news release includes forward-looking statements that are made pursuant to "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.*